000825208 001__ 825208
000825208 005__ 20210129225238.0
000825208 0247_ $$2DOI$$a10.1093/neuonc/now058
000825208 0247_ $$2WOS$$aWOS:000384005900008
000825208 0247_ $$2altmetric$$aaltmetric:6908275
000825208 0247_ $$2pmid$$apmid:27106405
000825208 037__ $$aFZJ-2016-07679
000825208 082__ $$a610
000825208 1001_ $$0P:(DE-HGF)0$$aAlbert, N. L.$$b0$$eCorresponding author
000825208 245__ $$aResponse Assessment in Neuro-Oncology (RANO) Working Group and European Association for Neuro-Oncology (EANO): Recommendations for the Clinical Use of PET Imaging in Gliomas
000825208 260__ $$aOxford$$bOxford Univ. Press$$c2016
000825208 3367_ $$2DRIVER$$aarticle
000825208 3367_ $$2DataCite$$aOutput Types/Journal article
000825208 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1483605335_4023
000825208 3367_ $$2BibTeX$$aARTICLE
000825208 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000825208 3367_ $$00$$2EndNote$$aJournal Article
000825208 520__ $$aThis guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) and amino acid tracers (11C-MET, 18F-FET, and 18F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas.
000825208 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000825208 7001_ $$0P:(DE-HGF)0$$aWeller, M.$$b1
000825208 7001_ $$0P:(DE-HGF)0$$aSuchorska, B.$$b2
000825208 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b3
000825208 7001_ $$0P:(DE-HGF)0$$aSoffietti, R.$$b4
000825208 7001_ $$0P:(DE-HGF)0$$aKim, M. M.$$b5
000825208 7001_ $$0P:(DE-HGF)0$$aLa Fugére, C.$$b6
000825208 7001_ $$0P:(DE-HGF)0$$aPope, W.$$b7
000825208 7001_ $$0P:(DE-HGF)0$$aLaw, I.$$b8
000825208 7001_ $$0P:(DE-HGF)0$$aArbizu, J.$$b9
000825208 7001_ $$0P:(DE-HGF)0$$aChamberlain, M.$$b10
000825208 7001_ $$0P:(DE-HGF)0$$aVogelbaum, M. A.$$b11
000825208 7001_ $$0P:(DE-HGF)0$$aEllingson, B. M.$$b12
000825208 7001_ $$0P:(DE-HGF)0$$aTonn, J. C.$$b13$$eCorresponding author
000825208 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/now058$$n9$$p1199 - 1208$$tNeuro-Oncology$$v18$$x1522-8517$$y2016
000825208 8564_ $$uhttps://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.pdf$$yRestricted
000825208 8564_ $$uhttps://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.gif?subformat=icon$$xicon$$yRestricted
000825208 8564_ $$uhttps://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000825208 8564_ $$uhttps://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.jpg?subformat=icon-180$$xicon-180$$yRestricted
000825208 8564_ $$uhttps://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.jpg?subformat=icon-640$$xicon-640$$yRestricted
000825208 8564_ $$uhttps://juser.fz-juelich.de/record/825208/files/Neuro%20Oncol-2016-Albert-1199-208.pdf?subformat=pdfa$$xpdfa$$yRestricted
000825208 909CO $$ooai:juser.fz-juelich.de:825208$$pVDB
000825208 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000825208 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000825208 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000825208 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000825208 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000825208 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000825208 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000825208 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000825208 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000825208 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000825208 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000825208 9141_ $$y2016
000825208 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b3$$kFZJ
000825208 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000825208 920__ $$lyes
000825208 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000825208 980__ $$ajournal
000825208 980__ $$aVDB
000825208 980__ $$aI:(DE-Juel1)INM-3-20090406
000825208 980__ $$aUNRESTRICTED